Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) received a $90.00 price target from research analysts at Canaccord Genuity in a report released on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price objective suggests a potential upside of 80.61% from the company’s previous close.

A number of other research analysts have also issued reports on the company. Oppenheimer Holdings, Inc. set a $75.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. Cowen and Company reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Thursday. Janney Montgomery Scott raised Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $57.00 price objective on the stock in a report on Thursday. Zacks Investment Research raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 27th. Finally, CIBC raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 17th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $63.54.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded up 5.12% during mid-day trading on Thursday, hitting $52.38. The company’s stock had a trading volume of 614,164 shares. The stock has a 50-day moving average of $43.46 and a 200-day moving average of $47.72. The company’s market cap is $2.20 billion. Agios Pharmaceuticals has a 12-month low of $34.31 and a 12-month high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, February 16th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.51) by $0.17. The business had revenue of $22.65 million for the quarter, compared to analyst estimates of $10.89 million. Agios Pharmaceuticals had a negative return on equity of 53.39% and a negative net margin of 341.56%. The company’s revenue for the quarter was up 264.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.08) earnings per share. On average, equities research analysts forecast that Agios Pharmaceuticals will post ($5.23) EPS for the current year.

“Agios Pharmaceuticals, Inc. (AGIO) Given a $90.00 Price Target by Canaccord Genuity Analysts” was reported by Financial Market News and is the property of of Financial Market News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The correct version of this piece of content can be viewed at http://www.financial-market-news.com/agios-pharmaceuticals-inc-agio-given-a-90-00-price-target-by-canaccord-genuity-analysts/1321582/.

A number of hedge funds have recently bought and sold shares of the company. Emerald Acquisition Ltd. purchased a new stake in Agios Pharmaceuticals during the second quarter worth approximately $319,000. Ameriprise Financial Inc. increased its stake in Agios Pharmaceuticals by 15.7% in the second quarter. Ameriprise Financial Inc. now owns 22,029 shares of the biopharmaceutical company’s stock worth $923,000 after buying an additional 2,983 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Agios Pharmaceuticals by 425.5% in the second quarter. JPMorgan Chase & Co. now owns 30,882 shares of the biopharmaceutical company’s stock worth $1,294,000 after buying an additional 25,005 shares during the last quarter. Teacher Retirement System of Texas increased its stake in Agios Pharmaceuticals by 40.8% in the second quarter. Teacher Retirement System of Texas now owns 3,921 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,136 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Agios Pharmaceuticals by 10.1% in the second quarter. Vanguard Group Inc. now owns 2,105,591 shares of the biopharmaceutical company’s stock worth $88,214,000 after buying an additional 192,852 shares during the last quarter. Institutional investors own 88.79% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.